Fast Five Quiz: Prognosis of Primary Myelofibrosis

Emmanuel C. Besa, MD


July 16, 2020

Clinical guidelines from the International Working Group–Myeloproliferative Neoplasms Research and Treatment and European LeukemiaNet state that appearance of a new splenomegaly that is palpable at least 5 cm below the left costal margin indicates progressive disease.

Progressive disease assignment for splenomegaly requires confirmation by CT or MRI showing a ≥ 25% increase in spleen volume from pretreatment baseline.

Learn more about how imaging studies may be used in the workup of a patient with PMF.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.